Chemical, Inhibitor

Rebastinib (DCC-2036)

  • Catalog Number : C4096
  • Number : C4096-50mg
  • Size:
    Qty :
  • Price : Request Inquiry
  • Download DataSheet print

Introduction

DCC-2036(Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. IC50 value: 0.8/4 nM (Abl1 wt/Abl1 T315I).It is an inhibitor of tyrosine kinases TIE2 and ABL1.Rebastinib(DCC2036) can prevent primary tumor growth and lung metastasis in the PyMT breast cancer model. Rebastinib is approximately 50 times more potent as an inhibitor of TIE2 than BCR-ABL.
Abl in vitro: DCC-2036 shows the potent inhibitory activities against purified native Abl1 in unphosphorylated (u-Abl1native) and phosphorylated (p-Abl1native) forms, unphosphorylated and phosphorylated gatekeeper mutant Abl1T315I, and the activation loop mutant Abl1H396P in a non-ATP-competitive manner with IC50 of 0.8 nM, 2 nM, 1.4 nM, 5 nM, and 4 nM, respectively. Moreover, DCC-2036 also inhibits the Src family kinases Src, LYN, FGR, and HCK, and the receptor TKs KDR, FLT3, and TIE2 with IC50 of 34 nM, 29 nM, 38 nM, 40 nM, 4 nM, 2 nM and 6 nM, respectively . A recent study shows that DCC-2036 shows the selectivity for growth inhibition of Bcr-Abl-positive cells by its marked inhibition of CML cell lines compared to non-CML leukemia lines.
in vivo: In a mouse allograft model bearing Ba/F3-Bcr-Abl1T315I leukemia cells, DCC-2036 treatment by oral gavage at 100 mg/kg once daily effectively inhibits Bcr-Abl1 signaling and significantly prolongs mouse survival.

General Information

Cas No. 1020172-07-9
Purity 98%
Molecular Weight 553.59
Formula C30H28FN7O3
Solubility 5mg/ml in DMSO
Storage instruction Store at -20 °C
Alias DCC2036,DCC 2036

Recently Viewed Products

gotop link
Customized Product Contact Us
0